Abstract:Cancer cells acquire immunoediting ability to evade immune surveillance and thus escape eradication. It is widely known that mutant proteins encoded from tumor suppressor TP53 exhibit gain-of-function in cancer cells, thereby promoting progression; however, how mutant p53 contributes to the sheltering of cancer cells from host anticancer immunity remains unclear. Herein, we report that murine p53 missense mutation G242A (corresponding to human G245A) suppresses the activation of host natural killer (NK) cells, thereby enabling breast cancer cells to avoid immune assault. We found that serial injection of EMT6 breast cancer cells that carry wild-type (wt) Trp53, like normal fibroblasts, promoted NK activity in mice, while SVTneg2 cells carrying Trp53 G242A+/+ mutation decreased NK cell numbers and increased CD8+ T lymphocyte numbers in spleen. Innate immunity based on NK cells and CD8 T cells was reduced in p53 mutant-carrying transgenic mice (Trp53 R172H/+, corresponding to human R175H/+). Further, upon co-culture with isolated NK cells, EMT6 cells substantively activated NK cells and proliferation thereof, increasing interferon-gamma (IFN-γ) production; however, SVTneg2 cells suppressed NK cell activation. Further mechanistic study elucidated that p53 can modulate expression by cancer cells of Mult-1 and H60a, which are activating and inhibitory ligands for NKG2D receptors of NK cells, respectively, to enhance immune surveillance against cancer. Our findings demonstrate that wt p53 is requisite for NK cell-based immune recognition and elimination of cancerous cells, and perhaps more importantly, that p53 missense mutant presence in cancer cells impairs NK cell-attributable responses, thus veiling cancerous cells from host immunity and enabling cancer progression.

P53 Mutation and Deletion Contribute to Tumor Immune Evasion

TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications

TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress

A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development

p53, cancer and the immune response

Functional Diversity of P53 in Human and Wild Animals

Tumor Suppressor P53 and Its Gain-of-function Mutants in Cancer

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe

Regulated secretion of mutant p53 negatively affects T lymphocytes in the tumor microenvironment

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

Tumor Suppressor P53 and Its Mutants in Cancer Metabolism.

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

Tumor Suppressor P53 Restrains Cancer Cell Dissemination by Modulating Mitochondrial Dynamics

Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant

p53 missense mutant G242A subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection

Mutant P53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Mutant p53 as a guardian of the cancer cell

Progress and Prospects: Roles of P53 in Tumor Development